Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 301–400 of 1,000
The role of natural killer cells in tumor control—effectors and regulators of adaptive immunity
Wallace, M. E., & Smyth, M. J. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0195-x · Cited by 95
“For example, NK cells activated through recognition of NKG2D ligands, such as Rae1, mediate their effects largely through perforin-dependent cytotoxicity [40], whereas activation of NK cells through specific recognition of CD70 results in critical IFN-g production [49].”
BackgroundInfluentialEvasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis
Zhu, M., Huang, Y., Bender, M. E., Girard, L., Kollipara, R. K., Eglenen-Polat, B., Naito, Y., Savage, T. K., Huffman, K. E., Koyama, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2808 · Cited by 87
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
“The enforced expression of the murine NKG2D ligand Rae1 on experimental tumors provokes rejection in wildtype animals through the coordinated activities of NK cells, CD8(1) T lymphocytes, and perforin, whereas the administration of anti-NKG2D blocking antibodies increases susceptibility to chemical carcinogens (136, 1…”
BackgroundEndothelial cells express NKG2D ligands and desensitize antitumor NK responses
Thompson, T. W., Kim, A. B., Li, P. J., Wang, J., Jackson, B. T., Huang, K. T. H., Zhang, L., & Raulet, D. H. (2017) · eLife · doi:10.7554/elife.30881 · Cited by 90
“In tumor transplant and spontaneous cancer models, expression of NKG2D ligand(s) on tumor cells triggers NK activation and protects the host from cancer (Diefenbach et al., 2001; Guerra et al., 2008).”
BackgroundSelf-citationArmeanu, S., Krusch, M., Baltz, K. M., Weiß, T. S., Smirnow, I., Steinle, A., Lauer, U. M., Bitzer, M., & Salih, H. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4744 · Cited by 95
Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance
Unni, A. M., Bondar, T., & Medzhitov, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701675105 · Cited by 80
Sun, S., Feng, Y., Xu, D., Zheng, H., & Li, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188700 · Cited by 87
Arreygue-Garcia, N., Daneri‐Navarro, A., Toro‐Arreola, A. D., Arregui, A. C., González‐Ramella, O., Jave‐Suárez, L. F., Aguilar‐Lemarroy, A., Troyo‐Sanromán, R., Bravo‐Cuéllar, A., Delgado‐Rizo, V., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-16 · Cited by 84
“NKG2D can promote tumor lysis by binding to a recently identified family of cell surface ligands encoded by the MHC class I chain-related (MIC) genes [21-23].”
BackgroundHuman Natural Killer Receptors, Co‐Receptors, and Their Ligands
Biassoni, R. (2009) · Current Protocols in Immunology · doi:10.1002/0471142735.im1410s84 · Cited by 82
“…retinoic acid early inducible (RAEα-ε) proteins, the minor histocomaptibility antigen H60, and the murine ULPB-like transcript 1 (MULT1) molecule (Nomura et al., 1996; Zou et al., 1996; Malarkannan et al., 1998; Cerwenka et al., 2000; Diefenbach et al., 2001, 2003; Carayannopoulos et al., 2002).”
BackgroundModeling cancer-immune responses to therapy
de Pillis, L. G., Eladdadi, A., & Radunskaya, A. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9386-9 · Cited by 86
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Bansal, D., Reimers, M. A., Knoche, E. M., & Pachynski, R. K. (2021) · Cancers · doi:10.3390/cancers13020334 · Cited by 85
“Membrane-bound and not tumor shed NKG2D ligand is thought to promote CD8 T cell and NK cell response [117].”
BackgroundÖberg, L., Johansson, S., Michaëlsson, J., Tomasello, E., Vivier, É., Kärre, K., & Höglund, P. (2004) · European Journal of Immunology · doi:10.1002/eji.200424913 · Cited by 90
A summary of current NKG2D-based CAR clinical trials
Curio, S., Jonsson, G., & Marinović, S. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab018 · Cited by 85
“The role of NKG2D and its ligands in tumor immunosurveillance has been demonstrated in animal models, where it was shown that NKG2DLs confer an effective barrier to tumor formation and that NKG2D deficiency results in a decreased ability to fight tumor cells [8,9].”
BackgroundMcCann, F. E., Eissmann, P., Önfelt, B., Leung, R., & Davis, D. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3418 · Cited by 90
The NKG2D receptor and its ligands–recognition beyond the “missing self”?
Watzl, C. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(02)00057-6 · Cited by 100
Cao, W., Xi, X., Hao, Z., Li, W., Kong, Y., Cui, L., Ma, C., Ba, D., & He, W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702504200 · Cited by 80
The re-polarisation of M2 and M1 macrophages and its role on cancer outcomes
den Breems, N. Y., & Eftimie, R. (2015) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2015.10.034 · Cited by 80
The Bone Microenvironment: a Fertile Soil for Tumor Growth
Buenrostro, D., Mulcrone, P. L., Owens, P., & Sterling, J. A. R. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0315-2 · Cited by 82
Harnessing dendritic cells in cancer
Apétoh, L., Locher, C., Ghiringhelli, F., Kroemer, G., & Zitvogel, L. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.01.003 · Cited by 89
Recruitment and Activation of Natural Killer Cells In vitro by a Human Dendritic Cell Vaccine
Gustafsson, K. U., Ingelsten, M., Bergqvist, L., Nystrom, J. C., Andersson, B. A., & Karlsson‐Parra, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6494 · Cited by 79
MMP9 mediates MICA shedding in human osteosarcomas
Sun, D., Wang, X., Zhang, H., Deng, L., & Zhang, Y. (2011) · Cell Biology International · doi:10.1042/cbi20100431 · Cited by 81
“When NKG2D binds to MICA, they constitute an immunosurveillance system for protecting the host from malignant cells and virus (Cerwenka et al., 2001; Diefenbach et al., 2001; Smyth et al., 2005).”
BackgroundA renaissance for the tumor immunosurveillance hypothesis
Lanier, L. L. (2001) · Nature Medicine · doi:10.1038/nm1101-1178 · Cited by 82
Strategies of Natural Killer Cell Recognition and Signaling
Stewart, C. A., Vivier, É., & Colonna, M. (2005) · Current topics in microbiology and immunology · doi:10.1007/3-540-27743-9_1 · Cited by 84
“NKG2D stimulation on NK cells leads to strong activation, and transfectionmediated NKG2D ligand expression on tumor cells leads to their rapid rejection in syngeneic mice (Cerwenka et al. 2001; Diefenbach et al. 2001).”
BackgroundMin, D., Lu, X., Wang, X., Zhang, B., Meng, W., Yu, F., & Hu, H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.337 · Cited by 79
“In mouse models, transfection with NKG2D ligands results in NKG2D-mediated tumour rejection (Cerwenka et al, 2001; Diefenbach et al, 2001).”
BackgroundThe Activating Immunoreceptor NKG2D and Its Ligands Are Involved in Allograft Transplant Rejection
Kim, J., Chang, C. K., Hayden, T. A., Liu, F., Benjamin, J., Hamerman, J. A., Lanier, L. L., & Kang, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6416 · Cited by 77
“Expression of RAE-1 on transplanted tumor cells markedly increases the ability of a host’s NK cells to kill these targets (8).”
BackgroundOgasawara, K., Yoshinaga, S. K., & Lanier, L. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3676 · Cited by 87
“Recent studies have shown that the stimulation of NK cells through NKG2D also allows NK cells to kill class I-positive tumors (35, 36); however, the effect of ICOS-dependent NK cell stimulation was less than that of NKG2D-dependent activation.”
BackgroundInnate Immune Recognition and Suppression of Tumors
Hayakawa, Y., & Smyth, M. J. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95008-8 · Cited by 83
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2014) · Bulletin of Mathematical Biology · doi:10.1007/s11538-014-0037-5 · Cited by 82
“The reason is that the cell lines used in the experiments do not normally express ligands of the NKG2D receptor (Diefenbach et al. 2001).”
BackgroundMethodResultInfluentialHuang, Y.-C., Hung, S.-W., Jan, T., Liao, K., Cheng, C., Wang, Y., & Chu, R. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0408255 · Cited by 81
“Activating receptors recognize specific ligands that are expressed on tumors and virus-infected cells, which provide an activation signal to NK cells [5].”
BackgroundHe, S., Yin, T., Li, D., Gao, X., Wan, Y., Ma, X., Ye, T., Guo, F., Sun, J., Lin, Z., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-186 · Cited by 75
“Engagement of NKG2D activates NK cells and then become a promising anti-cancer strategy [18,19].”
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Wang, X., Jasinski, D. L., Medina, J. L., Spencer, D. M., Foster, A. E., & Bayle, J. H. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001510 · Cited by 77
“NK cells eradicate neoplastic cells via several mechanisms: recognition of stress receptors on transformed cells, antigen-specific targeting through antibody-dependent cellular cytotoxicity, and expression of proapoptotic ligands.(15,41) This innate cytotoxicity provides a mechanism for CAR-NK cells to target tumor ce…”
BackgroundProteasome Regulation of ULBP1 Transcription
Butler, J. E., Moore, M. B., Presnell, S. R., Chan, H.-W., Chalupny, N. J., & Lutz, C. T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801214 · Cited by 69
Re-organization of mitochondria at the NK cell immune synapse
Abarca‐Rojano, E., Muñiz‐Hernández, S., Moreno‐Altamirano, M. M. B., Mondragón‐Flores, R., Enríquez-Rincón, F., & Sánchez‐García, F. J. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.10.008 · Cited by 80
Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation
Schmidt, L., Eskiocak, B., Kohn, R., Dang, C., Joshi, N. S., DuPage, M. J. P., Lee, D.-Y., & Jacks, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904253116 · Cited by 79
“The NKG2D activating receptor has been identified as one pathway by which NK cells recognize transformed cells for elimination (12, 13).”
Cadoux, M., Caruso, S., Pham, S., Gougèlet, A., Pophillat, C., Riou, R., Loesch, R., Colnot, S., Nguyễn, C. T., Caldéraro, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.017 · Cited by 83
Choi, E. Y., Christianson, G. J., Yoshimura, Y., Jung, N., Sproule, T. J., Malarkannan, S., Joyce, S., & Roopenian, D. C. (2002) · Blood · doi:10.1182/blood-2002-05-1299 · Cited by 75
Conejo-Garcia, J. R., Benencia, F., Courreges, M. C., Gimotty, P. A., Khang, E., Buckanovich, R. J., Frauwirth, K. A., Zhang, L., Katsaros, D., Thompson, C. B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2194 · Cited by 80
“NK cells may be responsible for rejection of tumors at early stages of malignant transformation (10, 22).”
BackgroundCytotoxic Immunity in Peripheral Nerve Injury and Pain
Davies, A. J., Rinaldi, S., Costigan, M., & Oh, S. B. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00142 · Cited by 77
“The homologous ligands in the mouse are separated into three families: Histocompatibility 60 (H-60) (Diefenbach et al., 2001), murine UL16-binding proteinlike transcript 1 (MULT1) (Carayannopoulos et al., 2002) and the RAE1 proteins family encoded by five Raet1 genes (α, β, γ, δ and ε) (Cerwenka et al., 2000).”
BackgroundERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors
Cifaldi, L., Romania, P., Falco, M., Lorenzi, S., Meazza, R., Petrini, S., Andreani, M., Pende, D., Locatelli, F., & Fruci, D. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1643 · Cited by 78
“Activating receptors recognize ligands on stressed, infected (4, 5), or transformed cells (6, 7), whereas inhibitory receptors, represented by killer cell Ig-like receptors (KIR) and CD94-NKG2A in humans (8–10) and Ly49 in mice (11), bind MHC-I molecules expressed on target cells (12).”
BackgroundStress Signals Activate Natural Killer Cells
Long, E. O., & Rajagopalan, S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021747 · Cited by 83
CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells
Chen, Z., Chen, L., Baker, K., Olszak, T., Zeißig, S., Huang, Y., Kuo, T. T., Mandelboim, O., Beauchemin, N., Lanier, L. L., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20102575 · Cited by 74
The Host Defense Peptide Cathelicidin Is Required for NK Cell-Mediated Suppression of Tumor Growth
Büchau, A. S., Morizane, S., Trowbridge, J., Schauber, J., Kotol, P., Bui, J. D., & Gallo, R. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902110 · Cited by 73
“RMA-Sisdeficient inMHC-Iexpression, and invivo tumordevelopment is controlledby NK cells (26), is not T cell dependent (7, 39), and has been used as a benchmark for invivoNKcell activity (40).”
MethodNK cells: An attractive candidate for cancer therapy
Valipour, B., Velaei, K., Abedelahi, A., Karimipour, M., Darabi, M., & Charoudeh, H. N. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28657 · Cited by 78
Xu, X., Rao, G. S., Groh, V., Spies, T., Gattuso, P., Kaufman, H. L., Plate, J., & Prinz, R. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-194 · Cited by 71
“Ectopic expression of NKG2D ligands Rae1b or H60 in several murine tumor cell lines leads to the sensitization of these cells to immune cell-mediated cytolysis and tumor rejection [13].”
BackgroundA Model of Dendritic Cell Therapy for Melanoma
de Pillis, L. G., Gallegos, A., & Radunskaya, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00056 · Cited by 73
“Using the same parameter values we determined through fitting to the data in Lee et al. (2007), a simulation of pre-vaccination with mature DCs showed no particular benefit.”
MethodWilkie, K. P., & Hahnfeldt, P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4590 · Cited by 76
“The second term accounts for innate immunity, and allows for a slow increase in the saturation limit with increasing immune presence, as seen when the lysis assays are conducted at larger ratios (3, 5, 6).”
Zhang, X., Wang, D., Li, Z., Jiao, D., Jin, L., Cong, J., Zheng, X., & Xu, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00331 · Cited by 77
“It has been reported that tumor cells with high expression of NKG2D ligands are rejected efficiently by NK cells, but that tumor cells with intermediate expression of NKG2D ligands are less immunogenic (15).”
BackgroundEvasion of myofibroblasts from immune surveillance: A mechanism for tissue fibrosis
Wallach‐Dayan, S. B., Golan‐Gerstl, R., & Breuer, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705582104 · Cited by 75
Mechanisms Involved in Synergistic Anticancer Immunity of Anti-4-1BB and Anti-CD4 Therapy
Choi, B. K., Kim, Y. H., Kang, W. J., Lee, S. K., Kim, K. H., Shin, S. M., Yokoyama, W. M., Kim, T. Y., & Kwon, B. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1056 · Cited by 74
“MHC-independent killing capability (13, 30, 31), although this aspect requires further investigation of the roles of authentic ligands such as RAE-1, H60, and MULT-1 (13, 32 , 33).”
BackgroundTumor immunotherapy: New aspects of natural killer cells
Li, Y., & Sun, R. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.02 · Cited by 76
JUNG, I. H., KIM, D. H., YOO, D. K., BAEK, S. Y., JEONG, S. H., JUNG, D. E., PARK, S. W., & CHUNG, Y.-Y. (2018) · In Vivo · doi:10.21873/invivo.11307 · Cited by 70
Girlanda, S., Fortis, C., Belloni, D., Ferrero, E., Ticozzi, P., Sciorati, C., Tresoldi, M., Vicari, A. M., Spies, T. A., Groh, V., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0731 · Cited by 72
“The relevance of NKG2D/NKG2D ligands in tumor immune surveillance has been outlined in animal models (40, 41 ) and also in the immunity against human hematologic malignancies (27–29).”
BackgroundStratikos, E., Stamogiannos, A., Zervoudi, E., & Fruci, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00363 · Cited by 73
“Mol Cell Proteomics (2012) 11(11):1416–29.”
Molecular Bases for the Regulation of NKG2D Ligands in Cancer
Huergo-Zapico, L., Acebes‐Huerta, A., López‐Soto, A., Villa-Ãlvarez, M. N., González, A. P., & Gonzalez, S. R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00106 · Cited by 80
Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion
Wilkie, K. P., & Hahnfeldt, P. (2013) · Interface Focus · doi:10.1098/rsfs.2013.0010 · Cited by 74
Bae, J.-H., Kim, J.-Y., Kim, M.-J., Chang, S.-H., Park, Y.-S., Son, C.-H., Park, S.-J., Chung, J.-S., Lee, E.-Y., Kim, S.-H., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32f22 · Cited by 68
Dhanji, S., & Teh, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3442 · Cited by 71
“The expression of the ligands for NKG2D, Rae-1, and H60 on tumor cells leads to their rejection in vivo by both NK cells and CD8 T cells (20, 32).”
BackgroundResultInfluentialPéraldi, M., Berrou, J., Dulphy, N., Seidowsky, A., Haas, P., Boissel, N., Métivier, F., Randoux, C., Kossari, N., Guérin, A. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1696 · Cited by 72
Zloza, A., Kohlhapp, F. J., Lyons, G. E., Schenkel, J. M., Moore, T. V., Lacek, A. T., O'Sullivan, J. A., Varanasi, V., Williams, J. W., Jagoda, M. C., et al. (2012) · Nature Medicine · doi:10.1038/nm.2683 · Cited by 66
Rodríguez‐Rodero, S., Gonzalez, S. R., Rodrigo, L., Fernández-Morera, J. L., Martínez-Borra, J., López‐Vázquez, A., & López‐Larrea, C. (2007) · European Journal of Immunology · doi:10.1002/eji.200737031 · Cited by 75
The emerging role of γδ T cells in cancer immunotherapy
Nussbaumer, O., & Koslowski, M. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.06.002 · Cited by 68
“lacking NKG2D show more susceptibility to spontaneous development of prostate cancer [28], and T cells and NK cells rapidly clear malignant cells injected intomice when they express NKG2D ligands [29].”
BackgroundTrotta, R., Chen, L., Costinean, S., Josyula, S., Mundy-Bosse, B. L., Ciarlariello, D., Mao, C., Briercheck, E. L., McConnell, K. K., Mishra, A., et al. (2013) · Blood · doi:10.1182/blood-2012-12-467597 · Cited by 69
“1(1)CD3(2) NK cells from miR-155 tg and wt mice for their ex vivo ability to kill the prototypic tumor cell target YAC-1, as well as the RMA tumor cell line that has high surface density expression of the NKG2D ligand Rae1b (RMA-Rae1b).(28) Fresh miR-155 tg NK cells lysed both YAC-1 (P, .”
BackgroundRaulet, D. H., Marcus, A., & Coscoy, L. (2017) · Immunological Reviews · doi:10.1111/imr.12600 · Cited by 65
Self-citationNatural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review
Uppendahl, L. D., Dahl, C. M., Miller, J. S., Felices, M., & Geller, M. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01825 · Cited by 72
Natural Killer Cell Alloreactivity for Leukemia Therapy
Ruggeri, L., Mancusi, A., Perruccio, K., Burchielli, E., Martelli, M. F., & Velardi, A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161395.88959.1f · Cited by 71
Functional visualization of NK cell-mediated killing of metastatic single tumor cells
Ichise, H., Tsukamoto, S., Hirashima, T., Konishi, Y., Oki, C., Tsukiji, S., Iwano, S., Miyawaki, A., Sumiyama, K., Terai, K., et al. (2022) · eLife · doi:10.7554/elife.76269 · Cited by 68
“In immunocompetent mice, selective depletion of NK cells markedly increases the metastatic burden (Diefenbach et al., 2001; Smyth et al., 1999).”
BackgroundThe Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
Tan, G., Spillane, K. M., & Maher, J. F. (2023) · Biology · doi:10.3390/biology12081079 · Cited by 79
Muntasell, A., Magri, G., Pende, D., Angulo, A., & López‐Botet, M. (2010) · Blood · doi:10.1182/blood-2009-11-256479 · Cited by 75
Immunological ignorance of solid tumors
Ochsenbein, A. F. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0192-0 · Cited by 70
“Immune surveillance by intraepithelial lymphocytes was activated by the murine NKG2d ligands Rae-1 and H60 [35, 36].”
BackgroundNKp80 defines and stimulates a reactive subset of CD8 T cells
Kuttruff, S., Koch, S. D., Kelp, A., Pawelec, G., Rammensee, H., & Steinle, A. (2008) · Blood · doi:10.1182/blood-2008-03-145615 · Cited by 64
The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma
Sheppard, S., Guedes, J., Mróz, A., Zavitsanou, A., Kudo, H., ROTHERY, S. M., Angelopoulos, P., Goldin, R. D., & Guerra, N. (2017) · Nature Communications · doi:10.1038/ncomms13930 · Cited by 69
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells
Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821b724a · Cited by 63
“An activating receptor NKG2D (natural killer group 2, member D) is expressed on human NK cells, CD8 T lymphocytes and gd T lymphocytes(7,12) and it has been known that the binding of NKG2D to its ligands may activate NK and T cells, and promote cytotoxic lysis of the target cells.(13) Eight distinct NKG2D ligands in h…”
BackgroundAdvances in NKG2D ligand recognition and responses by NK cells
Bert, N. L., & Gasser, S. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2013.111 · Cited by 64
Human Vγ9Vδ2 T cells: From signals to functions
Nédellec, S., Bonneville, M., & Scotet, E. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.04.004 · Cited by 63
Gomez-Santos, L., Luka, Z., Wagner, C., Fernandez-Alvarez, S., Lu, S. C., Mato, J. M., Martinez-Chantar, M. L., & Beraza, N. (2012) · Hepatology · doi:10.1002/hep.25694 · Cited by 61
Mixed immunotherapy and chemotherapy of tumors: Feedback design and model updating schemes
Chareyron, S., & Alamir, M. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.07.002 · Cited by 66
“The model recalled and described bellow is however based on published statements derived from clinical validations [ 9 ] [11] [22] as well as on reasonable assumptions depicted on table 1.”
Effect of splenectomy on antitumor immune system in mice.
Higashijima, J., Shimada, M., Chikakiyo, M., Miyatani, T., Yoshikawa, K., Nishioka, M., Iwata, T., & Kurita, N. (2009) · PubMed · Cited by 70
Ras Activation Induces Expression of Raet1 Family NK Receptor Ligands
Liu, X. V., Ho, S. S. W., Tan, J. J., Kamran, N., & Gasser, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200965 · Cited by 60
“When injected into mice, NKG2D ligand-expressing cells are rejected more efficiently by NK cells (39).”
BackgroundThe Paradoxical Role of NKG2D in Cancer Immunity
Sheppard, S., Ferry, A., Guedes, J., & Guerra, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01808 · Cited by 64
Siegler, U., Kalberer, C. P., Nowbakht, P., Sendelov, S., Meyer‐Monard, S., & Wodnar-Filipowicz, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403985 · Cited by 70
Alexandre, Y. O., Cocita, C., Ghilas, S., & Dalod, M. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00378 · Cited by 62
“In vivo, a specific expansion of Ly49H+ NK cells is observed at late time points after MCMV infection (Dokun et al., 2001).”
BackgroundBöll, B., Eltaib, F. I., Reiners, K. S., von Tresckow, B., Tawadros, S., Simhadri, V. R., Burrows, F. J., Lundgren, K., Hansen, H. P., Engert, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0213 · Cited by 67
Kelly, J. M., Takeda, K., Darcy, P. K., Yagita∥, H., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4472 · Cited by 69
Maccalli, C., Pende, D., Castelli, C., Mingari, M. C., Robbins, P. F., & Parmiani, G. (2003) · European Journal of Immunology · doi:10.1002/eji.200323909 · Cited by 62
Coordination of activating and inhibitory signals in natural killer cells
Chiesa, S., Tomasello, E., Vivier, É., & Vely, F. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.030 · Cited by 69
Immune Surveillance of Unhealthy Cells by Natural Killer Cells
Iannello, A., & Raulet, D. H. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.020255 · Cited by 54
“…surveillance of tumors by the demonstration that many tumors but few normal cells express NKG2D ligands (Bauer et al. 1999; Groh et al. 1999; Cerwenka et al. 2000; Diefenbach et al. 2000) and subsequently using subcutaneous tumor transfer models (Cerwenka et al. 2001; Diefenbach et al. 2001).”
Self-citationRitter, C., Fan, K., Paulson, K. G., Nghiem, P., Schrama, D., & Becker, J. C. (2016) · Scientific Reports · doi:10.1038/srep21678 · Cited by 63
“…an increased priming and activation of tumor-specific CD8 + T cells and long lasting T-cell memory responses even against NKG2D-negative tumor cells 47 : (i) Induction of NKG2D ligands on carcinoma cells boosts anti-tumor effects of CTLA-4 blockade 48 , and (ii) treatment with immune stimulating…”
Mathematical modeling and bifurcation analysis of pro- and anti-tumor macrophages
Shu, Y., Huang, J., Dong, Y., & Takeuchi, Y. (2020) · Applied Mathematical Modelling · doi:10.1016/j.apm.2020.06.042 · Cited by 71
Sharma, S., & Samanta, G. P. (2015) · Differential Equations and Dynamical Systems · doi:10.1007/s12591-015-0250-1 · Cited by 61
Endt, J., McCann, F. E., Almeida, C. R., Urlaub, D., Leung, R., Pende, D., Davis, D. M., & Watzl, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5606 · Cited by 69
The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance
Witalisz‐Siepracka, A., Klein, K., Moser, B., & Stoiber, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947568 · Cited by 62
Rothe, A., Jachimowicz, R. D., Borchmann, S., Madlener, M., Keßler, J., Reiners, K. S., Sauer, M., Hansen, H. P., Ullrich, R. T., Chatterjee, S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28609 · Cited by 63
Regulation of NKG2D Expression and Signaling by Endocytosis
Molfetta, R., Quatrini, L., Zitti, B., Capuano, C., Galandrini, R., Santoni, A., & Paolini, R. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.015 · Cited by 64
“The prominent role of NKG2D in tumor immune surveillance was first demonstrated in murine models by ectopic expression of NKG2D ligands, and this was found to be sufficient to cause tumor rejection in syngeneic mice [5,6].”
BackgroundSyder, A. J., Oh, J. D., Guruge, J. L., O'Donnell, D., Karlsson, M., Mills, J. C., Björkholm, B. M., & Gordon, J. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230380100 · Cited by 59
The Ugly Duckling Turned to Swan: A Change in Perception of Bystander-Activated Memory CD8 T Cells
Maurice, N. J., Taber, A. K., & Prlic, M. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000937 · Cited by 61
Das, P., Das, S., Das, P., Rihan, F. A., Uzuntarla, M., & Ghosh, D. (2021) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2021.110789 · Cited by 61
Zhang, W., Zhao, Z., & Li, F. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.02.015 · Cited by 64
Schumacher, L., Vo, D. D., Garbán, H., Comín-Anduix, B., Owens, S. K., Dissette, V. B., Glaspy, J. A., McBride, W. H., Bonavida, B., Economou, J. S., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4757 · Cited by 60
The Natural Selection of Herpesviruses and Virus-Specific NK Cell Receptors
Sun, J. C., & Lanier, L. (2009) · Viruses · doi:10.3390/v1030362 · Cited by 59
“In mice, the RAE-1 family of gene products, along with MULT1 and H60, constitute the stress-induced ligands of NKG2D, which are strongly induced during viral infection[24-27].”
BackgroundDai, C., Lin, F., Geng, R., Ge, X., Tang, W., Chang, J., Wu, Z., Liu, X., Lin, Y., Zhang, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7243 · Cited by 61
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.